Prophylactic Ketorolac Post Epiretinal Membrane Surgery
- Registration Number
- NCT00974753
- Lead Sponsor
- Queen's University
- Brief Summary
Evaluate the efficacy of ketorolac 0.5%, a topical non-steroidal anti-inflammatory drug (NSAID), to prevent macular edema after epiretinal membrane surgery. Patients undergoing epiretinal membrane surgery have increased risk of macular swelling which can adversely affect vision. Since post-intraocular surgery inflammation is a contributing factor to macular swelling and loss of vision, NSAID drops may be able to prevent or minimize the deleterious effects of macular swelling after epiretinal membrane surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
- idiopathic epiretinal membrane diagnosis requiring membrane peel surgery
Exclusion Criteria
- proliferative diabetic retinopathy
- sickle cell retinopathy
- radiation retinopathy
- choroidal folds
- hypersensitivity or allergy to NSAIDs
- wet macular degeneration
- branch retinal vein occlusion (BRVO)
- central retinal vein occlusion (CRVO)
- complicated membrane peel surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PPV-MP + Ketorolac 0.5% Ketorolac 0.5% PPV-MP= pars plana vitrectomy membrane peel PPV-MP + Placebo (Saline drops) Saline drops PPV-MP= pars plana vitrectomy membrane peel PhacoVit-MP + Placebo (Saline drops) Saline drops PhacoVit-MP= phacovitrectomy membrane peel PhacoVit-MP + Ketorolac 0.5%. Ketorolac 0.5% PhacoVit-MP= phacovitrectomy membrane peel
- Primary Outcome Measures
Name Time Method Change in macular volume from baseline. Before surgery, at 1 week, 1 month, and 1 year after surgery.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Ophthalmology, Hotel Dieu Hospital, Queen's University
🇨🇦Kingston, Ontario, Canada